Cite
HARVARD Citation
Loverix, L. et al. (n.d.). 2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer. International journal of gynecological cancer. p. A51. [Online].